214 related articles for article (PubMed ID: 37552363)
21. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.
Kim JM; Miller JA; Kotecha R; Xiao R; Juloori A; Ward MC; Ahluwalia MS; Mohammadi AM; Peereboom DM; Murphy ES; Suh JH; Barnett GH; Vogelbaum MA; Angelov L; Stevens GH; Chao ST
J Neurooncol; 2017 Jun; 133(2):357-368. PubMed ID: 28434110
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy.
Yusuf M; Rattani A; Gaskins J; Oliver AL; Mandish SF; Burton E; May ME; Williams B; Ding D; Sharma M; Miller D; Woo S
J Neurooncol; 2022 Jan; 156(1):163-172. PubMed ID: 34807342
[TBL] [Abstract][Full Text] [Related]
23. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
[TBL] [Abstract][Full Text] [Related]
24. First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases.
Sharma M; Jia X; Ahluwalia M; Barnett GH; Vogelbaum MA; Chao ST; Suh JH; Murphy ES; Yu JS; Angelov L; Mohammadi AM
Cancer Med; 2017 Sep; 6(9):2076-2086. PubMed ID: 28776956
[TBL] [Abstract][Full Text] [Related]
25. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.
Weingarten N; Kruser TJ; Bloch O
Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.
Minniti G; Paolini S; D'Andrea G; Lanzetta G; Cicone F; Confaloni V; Bozzao A; Esposito V; Osti M
J Neurooncol; 2017 May; 132(3):455-462. PubMed ID: 28260130
[TBL] [Abstract][Full Text] [Related]
27. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
28. Risk of symptomatic radiation necrosis in patients treated with stereotactic radiosurgery for brain metastases.
Sayan M; Şahin B; Mustafayev TZ; Kefelioğlu EŞS; Vergalasova I; Gupta A; Balmuk A; Güngör G; Ohri N; Weiner J; Karaarslan E; Özyar E; Atalar B
Neurocirugia (Astur : Engl Ed); 2021; 32(6):261-267. PubMed ID: 34743823
[TBL] [Abstract][Full Text] [Related]
29. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis.
Bodensohn R; Werner S; Reis J; Pazos Escudero M; Kaempfel AL; Hadi I; Forbrig R; Manapov F; Corradini S; Belka C; Theurich S; Heinzerling L; Schlaak M; Niyazi M
Clin Transl Radiat Oncol; 2023 Mar; 39():100573. PubMed ID: 36655118
[TBL] [Abstract][Full Text] [Related]
31. Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort.
Balermpas P; Stera S; Müller von der Grün J; Loutfi-Krauss B; Forster MT; Wagner M; Keller C; Rödel C; Seifert V; Blanck O; Wolff R
PLoS One; 2018; 13(6):e0198692. PubMed ID: 29874299
[TBL] [Abstract][Full Text] [Related]
32. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
33. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
[TBL] [Abstract][Full Text] [Related]
34. Radiation necrosis and therapeutic outcomes in patients treated with linear accelerator-based hypofractionated stereotactic radiosurgery for intact intracranial metastases.
Zhang Q; Hamilton D; Conway P; Xie SJ; Haghighi N; Lasocki A
J Med Imaging Radiat Oncol; 2023 Apr; 67(3):308-319. PubMed ID: 36847751
[TBL] [Abstract][Full Text] [Related]
35. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study.
Cohen-Inbar O; Lee CC; Mousavi SH; Kano H; Mathieu D; Meola A; Nakaji P; Honea N; Johnson M; Abbassy M; Mohammadi AM; Silva D; Yang HC; Grills I; Kondziolka D; Barnett GH; Lunsford LD; Sheehan J
J Neurosurg; 2017 Mar; 126(3):744-754. PubMed ID: 27104850
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases.
Hirata M; Yasui K; Oota N; Ogawa H; Onoe T; Maki S; Ito Y; Hayashi K; Asakura H; Murayama S; Mitsuya K; Deguchi S; Nakamura K; Hayashi N; Nishimura T; Harada H
Radiat Oncol; 2022 Dec; 17(1):213. PubMed ID: 36578021
[TBL] [Abstract][Full Text] [Related]
38. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
39. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
Burke AM; Carrasquilla M; Jean WC; Collins BT; Anaizi AN; Atkins MB; Gibney GT; Collins SP
Front Oncol; 2021; 11():794615. PubMed ID: 35096594
[TBL] [Abstract][Full Text] [Related]
40. Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases.
Dohm AE; Hughes R; Wheless W; Lecompte M; Lanier C; Ruiz J; Watabe K; Xing F; Su J; Cramer C; Laxton A; Tatter S; Chan MD
J Neurooncol; 2018 Dec; 140(3):749-756. PubMed ID: 30367382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
